AMG 330

DRUG2 trials

Sponsors

Amgen

Conditions

Minimal Residual Disease Positive AMLMyelodysplastic SyndromeRelapsed or Refractory Acute Myeloid LeukemiaRelapsed/Refractory AML

Phase 1

A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies

TerminatedNCT02520427

AmgenMinimal Residual Disease Positive AML, Myelodysplastic Syndrome, Relapsed/Refractory AML

Start: 2015-08-31End: 2022-01-09Updated: 2024-07-31

Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia

TerminatedNCT04478695

AmgenRelapsed or Refractory Acute Myeloid Leukemia

Start: 2020-09-29End: 2020-10-23Updated: 2024-03-08

Related Papers

Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436

Cancers2021-10-218 citations

Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed/refractory acute myeloid leukemia (R/R AML).

Journal of Clinical Oncology2020-05-20104 citations

Characterization of clinical pharmacokinetics and exposure-response relationships of AMG 330, a bispecific CD33 T-cell engager antibody construct, in patients with relapsed/refractory AML.

Journal of Clinical Oncology2020-05-202 citations

Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia.

2020-04-2977 citations

Antikörper-basierte Immuntherapie in der AML

Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München)2019-01-01

CD 33 in der akuten melodischen Leukämie

Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München)2017-01-01